InsomniaSleepMORENCT06373718
Sleep Mechanisms Of Regulating Emotions
A study testing Cognitive Behavioral Therapy for Insomnia in people with Insomnia and Depression, run by Stanford University at 1 site in United States.
Trial summary
This project is the second phase of a two-phased project investigating the impact of a proven sleep intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I) on engagement of the emotion regulation brain network as a putative mechanistic target. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Insomnia, Depression
- What is being tested?
- Cognitive Behavioral Therapy for Insomnia
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Aug 2024to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males and females of any racial or ethnic group, aged 18-65
- Subjective complaint of insomnia associated with daytime impairment or distress (ISI ≥ 10)
- Insomnia complaint ≥ 3 months in duration
- Subjective complaint of depressive symptoms as defined by scores of ≥ 14 on the BDI
- Fluent and literate in English
- Written, informed consent
- Reside within 60 miles of Stanford University
Who cannot join
- Presence of other sleep or circadian rhythm disorders that significantly contribute to their sleep disturbance. The presence of these disorders will be assessed by the DUKE structured interview for sleep disorders
- Use of psychotropic medications that would significantly impact sleep, alertness, or mood and unwilling or unable to discontinue medication specifically prescribed for sleep disturbance > two weeks (anti-depressants) or >1 week (sleep medications) prior to baseline data collection
- Excessive alcohol consumption (>14 drinks per week or > 4 drinks per occasion)
- Presence of suicidal ideations representing imminent risk as determined by the empirically-supported, standardized suicide risk assessment
- General medical condition, disease or neurological disorder that interferes with the assessments
- Substance abuse or dependence
Show all 16Show fewer
- History of significant head trauma followed by persistent neurological deficits or known structural brain abnormalities OR traumatic brain injury in the past two months
- Severe impediment to vision, hearing and/or hand movement, likely to interfere with the ability to complete the assessments, or are unable and/or unlikely to follow the study protocols
- Pregnant or breast feeding
- Current or lifetime history of bipolar disorder or psychosis
- Current or expected cognitive behavior therapy or other evidence-based psychotherapies for another condition
- Received cognitive behavioral therapy for insomnia within the past year
- Acute or unstable chronic illness: including but not limited to: uncontrolled thyroid disease, kidney, prostate or bladder conditions causing excessively frequent urination (> 3 times per night); medically unstable congestive heart failure, angina, other severe cardiac illness as defined by treatment regimen changes in the prior 3 months; stroke with serious sequelae; cancer if < 1 year since end of treatment; asthma, emphysema, or other severe respiratory diseases uncontrolled with medications; and neurological disorders such as Alzheimer's disease, Parkinson's disease and unstable epilepsy as defined by treatment regimen changes in the prior 3 months; unstable adult onset diabetes as defined by treatment regimen changes in the prior 3 months
- Current exposure to trauma, or exposure to trauma within the past 3 months
- Working a rotating shift that overlaps with 2400h
- Individuals who were high risk for sleep apnea on the Berlin Questionnaire and are not CPAP adherent or have untreated OSA of moderate severity or worse (AHI ≥ 15)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Leah Harris contact
United States1 site, 1 recruiting
- Recruiting
Stanford University
Palo Alto, California, 94304
Kaela Mandler, kaelam@stanford.edu
Andrea Goldstein-Piekarski, PhD
About this study
Official title: A Novel Use of a Sleep Intervention to Target the Emotion Regulation Brain Network to Treat Depression and Anxiety (R33 Phase)
This project is the second phase of a two-phased project investigating the impact of a proven sleep intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I) on engagement of the emotion regulation brain network as a putative mechanistic target.
Read the detailed description
Several lines of evidence suggest that insomnia contributes to emotionally distressing depressive mood symptoms through disruption of brain networks that regulate emotional functions. Of particular concern, insomnia is associated with an increased risk for suicide, even when accounting for the presence of other depressive symptoms. However, it is not yet know to what degree that the emotion regulation brain network is modified by the restoration of sleep, or whether the degree to which a sleep intervention engages these neural targets mediates reductions in depressive symptoms and suicidality.
This project is the second phase of a two-phased project investigating the impact of a proven sleep intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I) on engagement of the emotion regulation brain network as a putative mechanistic target.
This project aims to extend the initial findings from the first phase (IRB-56961) to (1) confirm target engagement, defined as the treatment effect on increasing mPFC-amygdala connectivity, and/or decreasing amygdala reactivity during emotion reactivity and regulation paradigms, by testing the hypothesis that compared with a control condition, CBT-I participants will show significant change in the emotion regulation network targets that met the Go Criteria of the first phase in the direction of normalization, at the end of treatment, (2) examine the relationships of target engagement to treatment outcomes by study group, and (3) test whether emotion regulation network measures at baseline predict depressive symptom and suicidality reduction.
Participants will be 120 adults experiencing at least moderate sleep disturbances and who also have elevated anxious and/or depressive symptoms. Eligible participants will be randomized into either the Immediate Treatment group, which will receive six sessions of CBT-I over the eight weeks of treatment phase immediately after randomization, or the Enhanced Sleep Hygiene group, which will be provided with two sessions of sleep hygiene / sleep education and four additional meetings including monitoring of sleep and mood symptoms and will be offered the same CBT-I as the Immediate Treatment group upon completion of the 6-month follow-up session, approximately 7 months after randomization. Emotion distress and sleep disruption will be assessed prior to, and weekly during the eight weeks of treatment phase. CBT-I improves sleep patterns through a combination of sleep restriction, stimulus control, mindfulness training, cognitive therapy targeting dysfunctional beliefs about sleep, and sleep hygiene education. Using fMRI scanning, emotion regulation network neural targets will be assayed prior to and following completion of CBT-I treatment.
- Conditions
- Insomnia, Depression
- Being tested
- Cognitive Behavioral Therapy for Insomnia
- Keywords
- Insomnia, Depression, Anxiety, CBT-I, Cognitive Behavioral Therapy for Insomnia
- Medical subject headings
- Sleep Initiation and Maintenance Disorders, Depression, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive Behavioral Therapy for InsomniaBehavioural
Also called CBT-I
CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
| Study group | Role | What they receive |
|---|---|---|
| Immediate Treatment | Experimental | Participants randomized to the Immediate Treatment group will receive CBT-I treatment immediately after randomization. Receives: Behavioral: Cognitive Behavioral Therapy for Insomnia |
| Enhanced Sleep Hygiene | Other | Participants randomized to the Enhanced Sleep Hygiene (ESH) group will be offered the same CBT-I described above approximately 7 months after being randomized. We will also provide a list of referrals for treatment upon completion of their end of treatment visit (approx. week 11) should they choose to seek treatment sooner. In the interim, they will be provided with two sessions of sleep hygiene / sleep education and four additional meetings including monitoring of sleep and mood symptoms. Receives: Behavioral: Cognitive Behavioral Therapy for Insomnia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Emotion Regulation Network brain activation as assessed by functional magnetic resonance imaging
During functional magnetic resonance imaging the Emotion Regulation Network will be engaged by emotional tasks, and circuit activation will be quantified by blood flow in regions of interest.
Measured: Assessed at baseline (week 1) and end of treatment (week 13)
Change in Emotion Regulation Network brain connectivity as assessed by functional magnetic resonance imaging
During functional magnetic resonance imaging the Emotion Regulation Network will be engaged by emotional tasks, and circuit connectivity will be quantified by the correlation of the blood flow between regions of interest.
Measured: Assessed at baseline (week 1) and end of treatment (week 13)
Change in Beck Depression Inventory
This measure is of the Beck Depression Inventory-II total score after excluding one sleep item. The average item score for the remaining 20 items will be multiplied by 21 (the original number of items), to create a modified depression scale that maintains the original range (ranges: 0-13 minimal, 14-19 mild, 20-28 moderate, and 29-63 severe).
The BDI-II is a 21-item self-report scale with high validity and reliability that assesses the severity of depression symptoms. The depression items consist of: sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, indecisiveness, worthlessness, loss of energy, irritability, changes in appetite, concentration difficulty, tiredness or fatigue, and loss of interest in sex. Items are scored from 0 to 3, and higher scores indicate greater levels of severity.
Measured: Assessed at baseline (week 1), throughout treatment phase (weeks 3-11), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Sleep Efficiency
Sleep efficiency (SE) is the percentage of total time in bed actually spent sleeping. Based on the overnight PSG sleep recording, SE will be calculated as the total time (minutes) spent asleep (sum of Stages N1, N2, N3, and REM) divided by the total time (minutes) in bed, and multiplied by 100.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Insomnia Severity Index (ISI) Scale Score
Subjective ratings of sleep disturbance and insomnia severity will be assessed with the Insomnia Severity Index. The Insomnia Severity Index (ISI) is a 7-item self-report measure of insomnia type, severity, and impact on functioning. The items consist of severity of sleep onset, sleep maintenance, early morning awakenings, sleep dissatisfaction, interference with daytime functioning, noticeability of sleep problems by others, and distress caused by sleep difficulties. Items are scored from 0 to 4 (0 = no problem, 4 = very severe problem). Score ranges of insomnia are: 0-7 absent, 8-14 sub-threshold, 15-21 moderate, and 22-28 severe. The ISI has good validity and reliability.
Measured: Assessed at baseline (week 1), throughout treatment phase (weeks 3-11), end of treatment (week 13), and 6-month follow-up (week 39)
Secondary outcomes (15)
Change in Columbia Suicide Severity Rating Scale
The Columbia Suicide Severity Rating Scale is a 12-item checklist that was designed to quantify the severity of suicidal ideation and behavior. It is composed of two parts. The first six questions ask about suicidal ideation and behavior in the past month while the last six questions ask about suicidal ideation and behavior since the last visit. The CSSRS has been proven to be reliable and valid. It has also been shown to have high sensitivity and specificity to the different suicidal behavior classifications.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Sleep Onset Latency (SOL) as a Measure of Sleep Continuity
Sleep Onset Latency (SOL) is the time (minutes) from "lights out" to actually falling asleep (sleep onset).
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Number of Arousals as a Measure of Sleep Continuity
Number of Arousals is determined by number of times of awakening as seen on the actigraph data.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Wake After Sleep Onset (WASO) as a Measure of Sleep Continuity
Wake After Sleep Onset (WASO) are periods of wakefulness occurring after sleep onset, before final awakening (sleep offset).
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Total Sleep Time (TST) as a Measure of Sleep Continuity
Total Sleep Time (TST) is the total time spent asleep, from the start of sleep onset to sleep offset subtracting any periods of wakefulness.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Sleep Efficiency (SE) as a Measure of Sleep Continuity
Sleep Efficiency (SE) is calculated as TST divided by total time spent in bed, multiplied by 100.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Sleep Onset Latency (SOL) as a Measure of Sleep Architecture
Sleep Onset Latency (SOL) is the time (minutes) from "lights out" or start of total recording time, to actually falling asleep as indicated by EEG changes.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Number of Arousals as a Measure of Sleep Architecture
Number of Arousals is determined by number of times of awakening by EEG changes.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Wake After Sleep Onset (WASO) as a Measure of Sleep Architecture
Wake After Sleep Onset (WASO) are periods of wakefulness occurring after sleep onset, before final awakening (sleep offset) measured by EEG changes.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Total Sleep Time (TST) as a Measure of Sleep Architecture
Total Sleep Time (TST) is the total time (minutes) spent asleep, from the start of sleep onset to sleep offset, subtracting any periods of wakefulness. TST includes stages N1, N2, N3, and REM sleep.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Sleep Efficiency (SE) as a Measure of Sleep Architecture
Sleep Efficiency (SE) is calculated as TST divided by total time spent in bed, multiplied by 100.
Duration of non-rapid eye movement (NREM) sleep includes stages N1, N2, and N3, and is measured in minutes. The duration of sleep outside of those stages that is associated with specific EEG stages is REM sleep.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Sleep Physiology measured by PSG
Topographical EEG power spectral density analysis associated with sleep stages will be calculated in the Delta (0.5-Hz), Theta (4-7Hz), Alpha (7-11Hz), Sigma (12-15Hz), Beta-1 (15-20Hz), Beta-2 (20-35Hz) and Gamma (35-45Hz) bands, according to published methods.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in 36-Item Short Form Survey (SF-36) Score
The SF-36 measures health-related quality of life based on eight domains: limitations in physical activities because of health problems, limitations in social activities because of physical or emotional problems, limitations in usual role activities because of physical health problems, bodily pain, general mental health (psychological distress and well-being), limitations in usual role activities because of emotional problems, vitality (energy and fatigue), and general health perceptions. Items are recoded then averaged together to create each scale. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Beck Anxiety Inventory
The BAI is a 21-item self-report scale that assesses the severity of anxiety symptoms.
Items are scored from 0 to 3 (0 = not at all, 3 = severe). Higher scores indicate greater levels of severity, and the ranges for anxiety levels are: 0-9 normal to minimal, 10-18 mild to moderate, 19-29 moderate to severe, and 30-63 severe. The BAI consists of two factors: somatic and cognitive.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Respiratory Sinus Arrhythmia (RSA)- measured by PSG
RSA is the phenomenon of an increased heart rate during inhalation and a decreased heart rate during exhalation. Since these fluctuations are controlled mainly by vagal influences on the heart, RSA serves as a reliable metric for measuring parasympathetic activity. RSA has been proven to be a reliable measure of emotion regulation and emotional responding in numerous studies.
Measured: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2024
- Study start12 Aug 2024
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InsomniaStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Enrolled participants will be randomized into either the Immediate Treatment group, or the Enhanced Sleep Hygiene group. Both study groups will receive CBT-I.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Principal investigator, Andrea Goldstein-Piekarski, Stanford University
- Investigators
- Andrea Goldstein, PhD, Principal investigator, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06373718
- Sponsor's protocol ID
- IRB-74553
- Other IDs
- R33MH120245
- Acronym
- SleepMORE
- Status last verified
- Apr 2026
- First submitted
- 15 Apr 2024
- Last updated
- 20 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Novel Use of a Sleep Intervention to Target the Emotion Regulation Brain Network to Treat Depression and Anxiety (R33 Phase)
- ClinicalTrials.gov ID
- NCT06373718
- Acronym / sponsor ID
- SleepMORE / IRB-74553
- Conditions
- Insomnia, Depression
- Keywords
- Insomnia, Depression, Anxiety, CBT-I, Cognitive Behavioral Therapy for Insomnia
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Study start
- 12 Aug 2024 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 18 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project is the second phase of a two-phased project investigating the impact of a proven sleep intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I) on engagement of the emotion regulation brain network as a putative mechanistic target.
Detailed description
Several lines of evidence suggest that insomnia contributes to emotionally distressing depressive mood symptoms through disruption of brain networks that regulate emotional functions. Of particular concern, insomnia is associated with an increased risk for suicide, even when accounting for the presence of other depressive symptoms. However, it is not yet know to what degree that the emotion regulation brain network is modified by the restoration of sleep, or whether the degree to which a sleep intervention engages these neural targets mediates reductions in depressive symptoms and suicidality.
This project is the second phase of a two-phased project investigating the impact of a proven sleep intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I) on engagement of the emotion regulation brain network as a putative mechanistic target.
This project aims to extend the initial findings from the first phase (IRB-56961) to (1) confirm target engagement, defined as the treatment effect on increasing mPFC-amygdala connectivity, and/or decreasing amygdala reactivity during emotion reactivity and regulation paradigms, by testing the hypothesis that compared with a control condition, CBT-I participants will show significant change in the emotion regulation network targets that met the Go Criteria of the first phase in the direction of normalization, at the end of treatment, (2) examine the relationships of target engagement to treatment outcomes by study group, and (3) test whether emotion regulation network measures at baseline predict depressive symptom and suicidality reduction.
Participants will be 120 adults experiencing at least moderate sleep disturbances and who also have elevated anxious and/or depressive symptoms. Eligible participants will be randomized into either the Immediate Treatment group, which will receive six sessions of CBT-I over the eight weeks of treatment phase immediately after randomization, or the Enhanced Sleep Hygiene group, which will be provided with two sessions of sleep hygiene / sleep education and four additional meetings including monitoring of sleep and mood symptoms and will be offered the same CBT-I as the Immediate Treatment group upon completion of the 6-month follow-up session, approximately 7 months after randomization. Emotion distress and sleep disruption will be assessed prior to, and weekly during the eight weeks of treatment phase. CBT-I improves sleep patterns through a combination of sleep restriction, stimulus control, mindfulness training, cognitive therapy targeting dysfunctional beliefs about sleep, and sleep hygiene education. Using fMRI scanning, emotion regulation network neural targets will be assayed prior to and following completion of CBT-I treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Enrolled participants will be randomized into either the Immediate Treatment group, or the Enhanced Sleep Hygiene group. Both study groups will receive CBT-I.
| Arm | Type | Receives |
|---|---|---|
| Immediate Treatment | Experimental | Behavioral: Cognitive Behavioral Therapy for InsomniaParticipants randomized to the Immediate Treatment group will receive CBT-I treatment immediately after randomization. |
| Enhanced Sleep Hygiene | Other | Behavioral: Cognitive Behavioral Therapy for InsomniaParticipants randomized to the Enhanced Sleep Hygiene (ESH) group will be offered the same CBT-I described above approximately 7 months after being randomized. We will also provide a list of referrals for treatment upon completion of their end of treatment visit (approx. week 11) should they choose to seek treatment sooner. In the interim, they will be provided with two sessions of sleep hygiene / sleep education and four additional meetings including monitoring of sleep and mood symptoms. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Males and females of any racial or ethnic group, aged 18-65
- Subjective complaint of insomnia associated with daytime impairment or distress (ISI ≥ 10)
- Insomnia complaint ≥ 3 months in duration
- Subjective complaint of depressive symptoms as defined by scores of ≥ 14 on the BDI
- Fluent and literate in English
Key exclusion criteria (16 listed)
- Presence of other sleep or circadian rhythm disorders that significantly contribute to their sleep disturbance. The presence of these disorders will be assessed by the DUKE structured interview for sleep disorders
- Use of psychotropic medications that would significantly impact sleep, alertness, or mood and unwilling or unable to discontinue medication specifically prescribed for sleep disturbance > two weeks (anti-depressants) or >1 week (sleep medications) prior to baseline data collection
- Excessive alcohol consumption (>14 drinks per week or > 4 drinks per occasion)
- Presence of suicidal ideations representing imminent risk as determined by the empirically-supported, standardized suicide risk assessment
- General medical condition, disease or neurological disorder that interferes with the assessments
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive Behavioral Therapy for InsomniaAlso: CBT-ICBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep. | Behavioural | Enhanced Sleep Hygiene, Immediate Treatment |
Primary outcome
Change in Emotion Regulation Network brain activation as assessed by functional magnetic resonance imaging
Time frame: Assessed at baseline (week 1) and end of treatment (week 13)
During functional magnetic resonance imaging the Emotion Regulation Network will be engaged by emotional tasks, and circuit activation will be quantified by blood flow in regions of interest.
Change in Emotion Regulation Network brain connectivity as assessed by functional magnetic resonance imaging
Time frame: Assessed at baseline (week 1) and end of treatment (week 13)
During functional magnetic resonance imaging the Emotion Regulation Network will be engaged by emotional tasks, and circuit connectivity will be quantified by the correlation of the blood flow between regions of interest.
Change in Beck Depression Inventory
Time frame: Assessed at baseline (week 1), throughout treatment phase (weeks 3-11), end of treatment (week 13), and 6-month follow-up (week 39)
This measure is of the Beck Depression Inventory-II total score after excluding one sleep item. The average item score for the remaining 20 items will be multiplied by 21 (the original number of items), to create a modified depression scale that maintains the original range (ranges: 0-13 minimal, 14-19 mild, 20-28 moderate, and 29-63 severe). The BDI-II is a 21-item self-report scale with high validity and reliability that assesses the severity of depression symptoms. The depression items consist of: sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or wishes, crying, agitation, loss of interest, indecisiveness, worthlessness, loss of energy, irritability, changes in appetite, concentration difficulty, tiredness or fatigue, and loss of interest in sex. Items are scored from 0 to 3, and higher scores indicate greater levels of severity.
Change in PSG Sleep Efficiency
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Sleep efficiency (SE) is the percentage of total time in bed actually spent sleeping. Based on the overnight PSG sleep recording, SE will be calculated as the total time (minutes) spent asleep (sum of Stages N1, N2, N3, and REM) divided by the total time (minutes) in bed, and multiplied by 100.
Change in Insomnia Severity Index (ISI) Scale Score
Time frame: Assessed at baseline (week 1), throughout treatment phase (weeks 3-11), end of treatment (week 13), and 6-month follow-up (week 39)
Subjective ratings of sleep disturbance and insomnia severity will be assessed with the Insomnia Severity Index. The Insomnia Severity Index (ISI) is a 7-item self-report measure of insomnia type, severity, and impact on functioning. The items consist of severity of sleep onset, sleep maintenance, early morning awakenings, sleep dissatisfaction, interference with daytime functioning, noticeability of sleep problems by others, and distress caused by sleep difficulties. Items are scored from 0 to 4 (0 = no problem, 4 = very severe problem). Score ranges of insomnia are: 0-7 absent, 8-14 sub-threshold, 15-21 moderate, and 22-28 severe. The ISI has good validity and reliability.
15 secondary outcomes
Change in Columbia Suicide Severity Rating Scale
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Sleep Onset Latency (SOL) as a Measure of Sleep Continuity
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Number of Arousals as a Measure of Sleep Continuity
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Wake After Sleep Onset (WASO) as a Measure of Sleep Continuity
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Total Sleep Time (TST) as a Measure of Sleep Continuity
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Actigraph Sleep Efficiency (SE) as a Measure of Sleep Continuity
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Sleep Onset Latency (SOL) as a Measure of Sleep Architecture
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Number of Arousals as a Measure of Sleep Architecture
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Wake After Sleep Onset (WASO) as a Measure of Sleep Architecture
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Total Sleep Time (TST) as a Measure of Sleep Architecture
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in PSG Sleep Efficiency (SE) as a Measure of Sleep Architecture
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Sleep Physiology measured by PSG
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in 36-Item Short Form Survey (SF-36) Score
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Beck Anxiety Inventory
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Change in Respiratory Sinus Arrhythmia (RSA)- measured by PSG
Time frame: Assessed at baseline (week 1), end of treatment (week 13), and 6-month follow-up (week 39)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Insomnia
Recruiting
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Nocturia, Insomnia
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)
Sleep Architecture, Mild Traumatic Brain Injury
RecruitingPhase 3
A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day
Insomia Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Leah Harris contact
Andrea Goldstein, PhD principal investigator
Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive Behavioral Therapy for Insomnia in people with Insomnia and Depression, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kaela Mandler (650-721-6089, kaelam@stanford.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Emotion Regulation Network brain activation as assessed by functional magnetic resonance imaging (time frame: Assessed at baseline (week 1) and end of treatment (week 13)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026.